An interventional study of Surgery with ELIOS laser in Glaucoma, sponsored by Hôpital Privé de la Baie. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Hôpital Privé de la Baie · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Glaucoma with a site in France — 10 open to participants now, 11 under way, none of them phase 3. Glaucoma · France.
Among the 54 studies in Glaucoma with a site in France, this one is the 24th largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2025, is one of 29 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 48th registered.
1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.
Browse Glaucoma studies →10 of the 54 studies in Glaucoma with a site in France are open now. Recruiting first, the newest first:
Hôpital Privé de la Baie · Sites in France
Ages 18+
University Hospital, Bordeaux · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18+
Hôpital Privé de la Baie · Sites in France
Ages 18+
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts · Sites in France
Ages 18–80 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 46 is below the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 105 across the 38 interventional studies, 120 across the 16 observational. Of the 36 that completed or were terminated, 8 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 54 have an industry lead sponsor. The 10 most frequent:
Hôpital Privé de la Baie is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Hôpital Privé de la Baie has 4 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
4 of the studies in Glaucoma with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06274593Nantes University HospitalStudy of OCT Peripapillary Angiography in Patients With Advanced Glaucoma | 2027-04-27 |
| NCT07802769University Hospital, BordeauxMagnetic Resonance Imaging of Cerebral Connectivity and Volume in Neurodegeneration and Glaucoma | 2027-05 |
| NCT04129021Centre Hospitalier National d'Ophtalmologie des Quinze-VingtsHigh Resolution, High-speed Multimodal Ophthalmic Imaging | 2027-07 |
| NCT07303257Hospices Civils de LyonQuality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 54 studies in Glaucoma with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Glaucoma is an irreversible optic neuropathy. It is the second most common cause of blindness worldwide. Glaucoma can be treated with topical medications (eye drops), laser or surgery. Traditional surgery is invasive and has a high complication rate (hypotonia, endophthalmitis, cataracts, etc.). As a result, several types of micro-invasive surgery (MIGS) have been developed to reduce the risks of surgery while maintaining their effectiveness in lowering intraocular pressure (IOP). The ELIOS laser system is the only ophthalmological excimer laser designed for the surgical treatment of glaucoma. The aim of the procedure is to ablate the trabecular meshwork and inner wall of Schlemm´s canal ab interno, with the creation of 10 microchannels of 210 um in the trabeculum using the ELIOS laser with a wavelength of 308 nm, in order to improve trabecular outflow to achieve a reduction in IOP. The ELIOS laser is an example of Microinvasive Glaucoma surgery (MIGS) with published results demonstrating efficacy and safety. The ELIOS laser is already in use in France (AMM / CE mark achieved). Its use as part of a prospective interventional study will enable us to collect data in order to treat patients more effectively and improve the quality of care provided to glaucoma patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Surgery with ELIOS laser
This surgery involves visualizing the iridocorneal angle before or after cataract surgery, inserting the ELIOS laser probe into the anterior chamber to come into slight contact with the trabecular meshwork, then pressing the foot pedal, the surgeon activates the laser, which creates a microchannel by photoablating the trabecular meshwork and inner wall of Schlemm´s canal (trabeculostomy) ± 210 um in diameter. This gesture is repeated until 10 microchannels are created. The creation of these microchannels enhances the natural outflow of aqueous humor by bypassing the site of major resistance in the system. The usual duration of the ELIOS procedure is typically few minutes). The rest of the surgery does not deviate from standard phacoemulsification.
Intraocular pressure (IOP)
This IOP measurement will be carried out using the Goldmann gold standard tonometer, in 2 measurements taken between 8am and 12am, and measured in mmHg
Time frame: day 0, 7 and 30, and month 3, 6 and 12 months after surgery
Quality of life
A quality of life questionnaire : 25 questions with Likert scales
Time frame: before and after surgery (1, 3, 6 and 12 months)
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.
Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 35 months is close to that.
Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hôpital Privé de la Baie